03-11-2008

The 2008 European Immunoassay Frost & Sullivan Excellence in Technology Award has been awarded to Chimera Biotec. Chimera Biotec is recognized for its pioneering Imperacer® ultra-sensitive immunoassay system, which has a 1000-fold better sensitivity compared to ELISA (Enzyme-linked ...

more

05-06-2008

For the third time Chimera Biotec supports the scientific community with a contest on ultra-sensitive immunoassays, the III. Immunolympics are open. The contest seeks to find potential solutions to today's scientific challenges using ultra-sensitive immunoassays. It's the third time that ...

more

European Commission supports study including 11 centres from 6 European countries

13-03-2007

Chimera Biotec joins the EU funded EDAR project to adapt the Imperacer(TM) platform technology for the detection of novel biomarkers for the diagnosis of Alzheimer's disease. The consortium wants to find out whether the new markers can be used to test efficacy of new drugs, thereby ...

more

14-09-2006

AvTech Laboratories, a division of Eurofins Scientific, and Chimera Biotec GmbH have signed a cooperation agreement that combines Chimera's ultra-high sensitive immunoassay technology, Imperacer, with AvTech's expertise in state-of-the-art analytical services. Under the agreement, AvTech will ...

more

Chimera Biotec and German Sports University developed a new and extremely sensitive technology for anti-doping testing

08-02-2006

Dr. Michael Adler, head of R&D at Chimera Biotec GmbH, Dortmund, Germany, and his group develop an ultra sensitive test for the detection of myostatin doping together with the team of Dr. Patrick Diel at the German Sports University, Cologne, Germany. The project, using Chimera IMPERACER ...

more